

Triviron Healthcare launches HPLC-based diagnostic solutions

01 June 2021 | News

The HPLC-based HbA1c analysers will be used for monitoring diabetes, thalassemia and haemoglobin variants



Triviron Healthcare has launched two new innovation-driven products for HbA1c and Hb variant detection. The new product includes NANO H5 & NANO H110 which are high-performance liquid chromatography analysers for HbA1c detection in less than three minutes. These HPLC-based HbA1c analysers will be used for monitoring diabetes, thalassemia and haemoglobin variants.

NANO H5, is a compact, automated HPLC analyser that uses ion exchange liquid chromatography for the quantitative determination of the glycosylated haemoglobin (HbA1c) in human whole blood with a processing time of 130 seconds that will expedite the laboratory TAT.

The fully automated analyser which promises to process five samples at a time will take Triviron Healthcare to reach the pinnacle of precision within a designated time frame in the global diagnostic market.

NANO H110 is a compact, automated HPLC analyser that has a dual test mode for HbA1c test and Hb Variant detection. It has some advanced facilities such as a barcode scanner and cap piercing with a high sample loading capacity of 110 samples at a time which make it suitable for laboratories with medium to large workloads.

Rajesh Patel, CEO (IVD Business), Triviron Healthcare on this occasion said, "Keeping in mind the increasing concern for the management of diabetes and the growing demand for accurate measurement of HbA1c level, today we are delighted to announce the launch of HPLC-based HbA1c analyzers - NANO H5 & NANO H110, that are compact and designed for precision."